A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants

This study is testing a new formulation of cabotegravir — a long-acting injectable HIV prevention and treatment medication — combined with an enzyme that may allow the injection to be given under the skin (subcutaneous) rather than into a muscle. This could make the injection easier to administer and more comfortable for patients. **You may be eligible if...** - You are between 18 and 55 years old - You are generally healthy with no significant medical conditions - You do not have HIV - You are not currently pregnant or at high risk of pregnancy during the study **You may NOT be eligible if...** - You have a history of significant heart, liver, kidney, or immune conditions - You have taken cabotegravir or similar HIV medications before - You have participated in another drug study recently - You have allergies to the study medications - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.